One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening
暂无分享,去创建一个
Ian H. Gilbert | Chidochangu P. Mpamhanga | William N. Hunter | Alan H. Fairlamb | Paul G. Wyatt | Ruth Brenk | I. Gilbert | A. Fairlamb | R. Brenk | W. Hunter | D. Robinson | P. Wyatt | J. Frearson | C. Mpamhanga | D. Spinks | Julie A. Frearson | Emma J. Shanks | I. Collie | David A. Robinson | Daniel Spinks | Lindsay B. Tulloch | Iain T. Collie | L. Tulloch | Emma Shanks
[1] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[2] Gordon A. Leonard,et al. Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites , 2001, Nature Structural Biology.
[3] Peter Willett,et al. Knowledge-Based Interaction Fingerprint Scoring: A Simple Method for Improving the Effectiveness of Fast Scoring Functions , 2006, J. Chem. Inf. Model..
[4] A. Fairlamb,et al. Chemical and genetic validation of dihydrofolate reductase–thymidylate synthase as a drug target in African trypanosomes , 2008, Molecular microbiology.
[5] Jin Li,et al. On Evaluating Molecular-Docking Methods for Pose Prediction and Enrichment Factors , 2006, J. Chem. Inf. Model..
[6] P. Hajduk,et al. Puzzling through fragment-based drug design , 2006, Nature chemical biology.
[7] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[8] Richard D. Taylor,et al. Virtual Screening Using Protein—Ligand Docking: Avoiding Artificial Enrichment. , 2004 .
[9] L. Hardy,et al. New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity , 1997, Parasitology.
[10] Beverley,et al. Biochemical and Genetic Tests for Inhibitors of Leishmania Pteridine Pathways , 1997, Experimental parasitology.
[11] Stephen M Beverley,et al. Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. , 2005, Journal of molecular biology.
[12] J. Donelson,et al. The Genome of the African Trypanosome , 2002 .
[13] A. Vagin,et al. MOLREP: an Automated Program for Molecular Replacement , 1997 .
[14] Paul R. Gerber,et al. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..
[15] Hanna Geppert,et al. Integrating Structure‐ and Ligand‐Based Virtual Screening: Comparison of Individual, Parallel, and Fused Molecular Docking and Similarity Search Calculations on Multiple Targets , 2008, ChemMedChem.
[16] G N Murshudov,et al. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. , 2001, Acta crystallographica. Section D, Biological crystallography.
[17] Kerim Babaoglu,et al. Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.
[18] Daniel James,et al. Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases , 2007, ChemMedChem.
[19] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[20] Thomas Sander,et al. Comparison of Ligand- and Structure-Based Virtual Screening on the DUD Data Set , 2009, J. Chem. Inf. Model..
[21] Paul R. Gerber,et al. Charge distribution from a simple molecular orbital type calculation and non-bonding interaction terms in the force field MAB , 1998, J. Comput. Aided Mol. Des..
[22] A. Fairlamb,et al. Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate , 2006, Molecular microbiology.
[23] R. Pink,et al. Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.
[24] S. Kurup,et al. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II. , 2008, Anti-cancer agents in medicinal chemistry.
[25] B. Shoichet,et al. Probing molecular docking in a charged model binding site. , 2006, Journal of molecular biology.
[26] A. Leslie,et al. The integration of macromolecular diffraction data. , 2006, Acta crystallographica. Section D, Biological crystallography.
[27] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[28] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[29] David M. A. Martin,et al. The Genome of the African Trypanosome Trypanosoma brucei , 2005, Science.
[30] P. Kuzmič,et al. High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants. , 2000, Analytical biochemistry.
[31] P. Kennedy. The continuing problem of human African trypanosomiasis (sleeping sickness) , 2008, Annals of neurology.
[32] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[33] L. Hardy,et al. PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[34] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[35] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[36] Maria Paola Costi,et al. Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development , 2008, Proceedings of the National Academy of Sciences.
[37] O. Balmer,et al. New developments in human African trypanosomiasis , 2006, Current opinion in infectious diseases.
[38] Christian R Noe,et al. In silico prediction models for blood-brain barrier permeation. , 2004, Current medicinal chemistry.
[39] B. Matthews,et al. A model binding site for testing scoring functions in molecular docking. , 2002, Journal of molecular biology.
[40] R. Titus,et al. Regulation of Differentiation to the Infective Stage of the Protozoan Parasite Leishmania major by Tetrahydrobiopterin , 2001, Science.
[41] B. Shoichet,et al. Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.
[42] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[43] R. Iemura,et al. Syntheses of the metabolites of 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H benzimidazole difumarate (KG-2413) and related compounds. , 1989, Chemical & pharmaceutical bulletin.
[44] L. Hardy,et al. The Roles of Pteridine Reductase 1 and Dihydrofolate Reductase-Thymidylate Synthase in Pteridine Metabolism in the Protozoan Parasite Leishmania major* , 1997, The Journal of Biological Chemistry.
[45] Gerhard F. Ecker,et al. In silico prediction models for blood-brain barrier permeation. , 2004, Current medicinal chemistry.
[46] P. Evans,et al. Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.
[47] A G Leslie,et al. Biological Crystallography Integration of Macromolecular Diffraction Data , 2022 .
[48] Ricardo L Mancera. Molecular modeling of hydration in drug design. , 2007, Current opinion in drug discovery & development.
[49] Gilles Marcou,et al. Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..
[50] S. Kurup,et al. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I. , 2007, Anti-cancer agents in medicinal chemistry.
[51] Robert P. Sheridan,et al. Comparison of Topological, Shape, and Docking Methods in Virtual Screening , 2007, J. Chem. Inf. Model..
[52] Pedro Alexandrino Fernandes,et al. Protein–ligand docking: Current status and future challenges , 2006, Proteins.
[53] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.